Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

John Gerecitano, Carol Portlock, Craig Moskowitz, Paul Hamlin, David Straus, Andrew D. Zelenetz, Zhigang Zhang, Otilia Dumitrescu, Debra Sarasohn, Dorothy Lin, Jennifer Pappanicholaou, Barbara M. Cortelli, Ellen Neylon, Rachel Hamelers, John Wright, Owen A. O'Connor

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

Original languageEnglish (US)
Pages (from-to)652-655
Number of pages4
JournalBritish Journal of Haematology
Issue number6
StatePublished - 2009
Externally publishedYes


  • Bortezomib
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma'. Together they form a unique fingerprint.

Cite this